5G3 logo

TalkMed Group Stock Price

Symbol: SGX:5G3Market Cap: S$611.9mCategory: Healthcare

5G3 Share Price Performance

5G3 Community Fair Values

    Recent 5G3 News & Updates

    No updates

    TalkMed Group Limited Key Details

    S$78.2m

    Revenue

    S$33.4m

    Cost of Revenue

    S$44.7m

    Gross Profit

    S$946.0k

    Other Expenses

    S$43.8m

    Earnings

    Last Reported Earnings
    Dec 31, 2024
    Next Reporting Earnings
    n/a
    Earnings per share (EPS)
    0.033
    Gross Margin
    57.22%
    Net Profit Margin
    56.01%
    Debt/Equity Ratio
    5.6%

    TalkMed Group Limited Competitors

     
     
     
     
     
     
     
     
     
     
     
     

    About 5G3

    Founded
    1997
    Employees
    235
    CEO
    Peng Tiam Ang
    WebsiteView website
    www.talkmed.com.sg

    TalkMed Group Limited, an investment holding company, provides medical oncology, stem cell transplants, palliative care, and other related services in Singapore, China, Hong Kong, Vietnam, New Zealand, Australia, and the United States. It operates in two segments: Oncology Services; and Cellular and Gene Therapy Related Products and Services. The company offers medical oncology services in the areas of breast, colon, lung, liver, biliary and pancreatic, gastro-intestinal, head and neck, genitourinary and gynaecological, and haematology malignancies and brain cancers, as well as lymphoma and leukaemia. It also provides palliative care services comprising cancer pain management, discharge and home care planning, advance care planning, and end-of-life care planning; and ancillary health services, such as CANSCREEN, a screening program that provides screening for individuals at a risk of getting cancer. In addition, the company offers products and services related to cellular and gene therapy; specialist doctors and clinical staff services; and healthcare management services. Further, it develops novel processing platforms for cell and gene therapy and carrying out research in genetic modification of immune cells; and novel platform viral vector technologies that strive to advance genetic modification of cellular therapy. TalkMed Group Limited was founded in 1997 and is based in Singapore. TalkMed Group Limited is a subsidiary of Citibank Nominees Singapore Pte Ltd.

    Singaporean Market Performance

    • 7 Days: -2.7%
    • 3 Months: 9.1%
    • 1 Year: 21.2%
    • Year to Date: 10.6%
    Over the last 7 days, the market has dropped 2.7%, driven by a pullback of 2.4% in the Financials sector. As for the longer term, the market has actually risen by 21% in the last year. As for the next few years, earnings are expected to grow by 7.1% per annum. Market details ›
    This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
    Continue reading